Completed PHASE3 INTERVENTIONAL 3-arm NCT00002850

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma

Sponsor: Eastern Cooperative Oncology Group

Interventions 160 mg trimethoprim and 800 mg sulfamethoxazole ciprofloxacin ofloxacin

Updated 6 times since 2017 Last updated: Oct 13, 2015 Started: Mar 31, 1997 Primary completion: Apr 30, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Infection and Multiple Myeloma and is currently completed. Eastern Cooperative Oncology Group leads this study, which shows 6 recorded versions since 1997 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Cooperative Oncology Group
Gary Morrow
National Cancer Institute (NCI)

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Canton, United States , Cedar Rapids, United States , Cleveland, United States , Columbus, United States , Dayton, United States , East Syracuse, United States , Escanaba, United States , Flemington, United States , Goldsboro, United States and 27 more locations